Publications

1. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, Ladany H, Chen D, Zatzman M, Cabric V, Nobre L, Bianchi V, Edwards M, Sambira Nahum LC, Ercan AB, Nabbi A, Constantini S, Dvir R, Yalon-Oren M, Campino GA, Caspi S, Larouche V, Reddy A, Osborn M, Mason G, Lindhorst S, Bronsema A, Magimairajan V, Opocher E, De Mola RL, Sabel M, Frojd C, Sumerauer D, Samuel D, Cole K, Chiaravalli S, Massimino M, Tomboc P, Ziegler DS, George B, Van Damme A, Hijiya N, Gass D, McGee RB, Mordechai O, Bowers DC, Laetsch TW, Lossos A, Blumenthal DT, Sarosiek T, Yen LY, Knipstein J, Bendel A, Hoffman LM, Luna-Fineman S, Zimmermann S, Scheers I, Nichols KE, Zapotocky M, Hansford JR, Maris JM, Dirks P, Taylor MD, Kulkarni AV, Shroff M, Tsang DS, Villani A, Xu W, Aronson M, Durno C, Shlien A, Malkin D, Getz G, Maruvka YE, Ohashi PS, Hawkins C, Pugh TJ, Bouffet E, Tabori U. 

Nat Med. 2022 Jan;28(1):125-135. doi: 10.1038/s41591-021-01581-6. Epub 2022 Jan 6. PMID: 34992263.

2. Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers

Kim SR, Tone A, Kim R, Cesari M, Clarke B, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE, Eiriksson L.

Int J Gynecol Cancer. 2022 Jan 10:ijgc-2021-003082. doi: 10.1136/ijgc-2021-003082. Epub ahead of print. PMID: 35012974.

3. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity

Hezaveh K, Shinde RS, Klötgen A, Halaby MJ, Lamorte S, Ciudad MT, Quevedo R, Neufeld L, Liu ZQ, Jin R, Grünwald BT, Foerster EG, Chaharlangi D, Guo M, Makhijani P, Zhang X, Pugh TJ, Pinto DM, Co IL, McGuigan AP, Jang GH, Khokha R, Ohashi PS, O’Kane GM, Gallinger S, Navarre WW, Maughan H, Philpott DJ, Brooks DG, McGaha TL.

Immunity. 2022 Feb 8;55(2):324-340.e8. doi: 10.1016/j.immuni.2022.01.006. PMID: 35139353.

4. All is not lost: learning from 9p21 loss in cancer

Spiliopoulou P, Yang SYC, Bruce JP, Wang BX, Berman HK, Pugh TJ, Siu LL.

Trends Immunol. 2022 Apr 1:S1471-4906(22)00052-7. doi: 10.1016/j.it.2022.03.003. PMID: 35379580. 

5. “Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management

Shickh S, Oldfield LE, Clausen M, Mighton C, Sebastian A, Calvo A, Baxter NN, Dawson L, Penney LS, Foulkes W, Basik M, Sun S, Schrader KA, Regier DA, Karsan A, Pollett A, Pugh TJ, Kim RH, Bombard Y; CHARM Consortium.

Oncologist. 2022 Apr 6:oyac039. doi: 10.1093/oncolo/oyac039. PMID: 35385106.

1. Coenzyme A fuels T cell anti-tumor immunity

St Paul M, Saibil SD, Han S, Israni-Winger K, Lien SC, Laister RC, Sayad A, Penny S, Amaria RN, Haydu LE, Garcia-Batres CR, Kates M, Mulder DT, Robert-Tissot C, Gold MJ, Tran CW, Elford AR, Nguyen LT, Pugh TJ, Pinto DM, Wargo JA, Ohashi PS.

Cell Metab. 2021 Dec 7;33(12):2415-2427.e6. doi: 10.1016/j.cmet.2021.11.010. PMID: 34879240.

2. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL, Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN.

Genome Med. 2021 Dec 3;13(1):186. doi: 10.1186/s13073-021-00998-5. PMID: 34861889

3. Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.

Croucher DC, Richards LM, Tsofack SP, Waller D, Li Z, Wei E, Huang XF, Chesi M, Bergsagel PL, Sebag M, Pugh TJ+, Trudel S+

Nature Communications. 2021 Nov; 12(6322). https://doi.org/10.1038/s41467-021-26598-w (SRA)

4. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.

Lee DD, Komosa M, Sudhaman S, Leao R, Zhang CH, Apolonio JD, Hermanns T, Wild PJ, Klocker H, Nassiri F, Zadeh G, Diplas BH, Yan H, Gallinger S, Pugh TJ, Ramaswamy V, Taylor MD, Castelo-Branco P, Nunes NM, Tabori U.

J Clin Invest. 2021 Nov;131(21):e146915. doi.org/10.1172/JCI146915. PMID: 34720085 (CA)

5. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.

Oliva M, Chepeha D, Araujo DV, Diaz-Mejia JJ, Olson P, Prawira A, Spreafico A, Bratman SV, Shek T, de Almeida J, R Hansen A, Hope A, Goldstein D, Weinreb I, Smith S, Perez-Ordoñez B, Irish J, Torti D, Bruce JP, Wang BX, Fortuna A, Pugh TJ, Der-Torossian H, Shazer R, Attanasio N, Au Q, Tin A, Feeney J, Sethi H, Aleshin A, Chen I, Siu L.

J Immunother Cancer. 2021 Oct;9(10):e003476. doi: 10.1136/jitc-2021-003476. PMID: 34599023 (CA)

6. HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA.

Leung E, Han K, Zou J, Zhao Z, Zheng Y, Wang TT, Rostami A, Siu LL, Pugh TJ, Bratman SV.

Clin Cancer Res. 2021 Sep 27. doi: 10.1158/1078-0432.CCR-19-2384. PMID: 34580115 (CA)

7. Mutations in Noncoding Cis-Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer.

El Ghamrasni S, Quevedo R, Hawley J, Mazrooei P, Hanna Y, Cirlan I, Zhu H, Bruce JP, Oldfield LE, Yang SYC, Guilhamon P, Reimand J, Cescon DW, Done SJ, Lupien M, Pugh TJ.

Mol Cancer Res. 2021 Sep 23. doi: 10.1158/1541-7786.MCR-21-0471. PMID: 34556523 (SRA)

8. Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.

Kim SR, Tone A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart TL, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.

Cancer. 2021 May 13;. doi: 10.1002/cncr.33625. PMID: 33983630. (CA)

9. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

SYC Yang, Lien SC, Wang B, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak ARA, Speers V, Hal K Berman HK, Haibe-Kains B, Brooks DG, McGaha T, Butler M, Bratman SV, Ohashi PS, Siu LL+, Pugh TJ+.

Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7. PMID: 34446728 (SRA)

10. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape.

Bruce JP, To KF, Lui VWY, Chung GTY, Chan YY, Tsang CM, Yip KY, Ma BBY, Woo JKS, Hui EP, Mak MKF, Lee SD, Chow C, Velapasamy S, Or YYY, Siu PK, El Ghamrasni S, Prokopec S, Wu M, Kwan JSH, Liu Y, Chan JYK, van Hasselt CA, Young LS, Dawson CW, Paterson IC, Yap LF, Tsao SW, Liu FF, Chan ATC, Pugh TJ+, Lo KW+.

Nat Commun. 2021 Jul 7;12(1):4193. doi: 10.1038/s41467-021-24348-6. PMID: 34234122. (SRA)

11. Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.

Campbell BB, Galati MA, Stone SC, Riemenschneider AN, Edwards M, Sudhaman S, Siddaway R, Komosa M, Nunes NM, Nobre L, Morrissy AS, Zatzman M, Zapotocky M, Joksimovic L, Kalimuthu SN, Samuel D, Mason G, Bouffet E, Morgenstern DA, Aronson M, Durno C, Malkin D, Maris JM, Taylor MD, Shlien A, Pugh TJ, Ohashi PS, Hawkins CE, Tabori U.

Cancer Discov. 2021 Jun;11(6):1454-1467. doi: 10.1158/2159-8290.CD-20-1050. PMID: 33563663. (CA)

12. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.

Kim SR, Tone A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Lajkosz K, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh T, Pollett A, Ferguson SE.

Gynecol Oncol. 2021 Apr;161(1):221-227. doi: 10.1016/j.ygyno.2021.01.002. PMID: 33478752. (CA)

13. The DEAD-box helicase DDX56 is a conserved stemness regulator in normal and cancer stem cells

Pryszlak M, Wiggans M, Chen X, Jaramillo JE, Burns S, Richards L, Pugh TJ, Kaplan DR, Huang X, Dirks PB Pearson BJ.

Cell Reports. 2021 Mar 30;34(13):108903. doi: 10.1016/j.celrep.2021.108903. PMID: 33789112. (CA)

14. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
Longo J, Smirnov P, Li Z, Branchard E, van Leeuwen JE, Licht JD, Haibe-Kains B, Andrews DW, Keats JJ, Pugh TJ, Trudel S, Penn LZ.

Leukemia. 2021 Mar;35(3):796-808. doi: 10.1038/s41375-020-0962-2. PMID: 32665698; PMCID: PMC7359767. (CA)

15. Elevation in Viral Entry Genes and Innate Immunity Compromise Underlying Increased Infectivity and Severity of COVID-19 in Cancer Patients

Kwan JY, Dr. Lin LT, Bell R, Bruce JP, Richardson C, Pugh TJ, Liu FF

Sci Rep. 2021 Feb 25;11(1):4533. doi: 10.1038/s41598-021-83366-y. (CA)

16. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.

Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L, Rastegar N, Vu V, Sánchez-Osuna M, Coulombe-Huntington J, Kanshin E, Whetstone H, Durand M, Thibault P, Hart K, Mangos M, Veyhl J, Chen W, Tran N, Duong BC, Aman AM, Che X, Lan X, Whitley O, Zaslaver O, Barsyte-Lovejoy D, Richards LM, Restall I, Caudy A, Röst HL, Bonday ZQ, Bernstein M, Das S, Cusimano MD, Spears J, Bader GD, Pugh TJ, Tyers M, Lupien M, Haibe-Kains B, Artee Luchman H, Weiss S, Massirer KB, Prinos P, Arrowsmith CH, Dirks PB.

Nat Commun. 2021 Feb 12;12(1):979. doi: 10.1038/s41467-021-21204-5. PMID: 33579912; PMCID: PMC7881162. (CA)

17. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.

Iafolla MAJ, Yang C, Chandran V, Pintilie M, Li Q, Bedard PL, Hansen A, Lheureux S, Spreafico A, Razak AA, Hakgor S, Giesler A, Pugh TJ, Siu LL.

JNCI Cancer Spectr. 2021 Feb;5(1):pkaa115. doi: 10.1093/jncics/pkaa115. eCollection 2021 Feb. PMID: 33554038; PMCID: PMC7853183. (CA)

18. An integrative DNA sequencing and methylation panel to assess mismatch repair deficiency

Oldfield LE, Li TT, Tone A, Aronson M, Dowar M, Edwards M, Holter S, Quevedo R, Van de Laar E, Lerner-Ellis J, Pollett A, Clarke B, Tabori U, Gallinger S, Ferguson S, Pugh TJ

JMD. 2021 Feb;23(2):242-252. doi: 10.1016/j.jmoldx.2020.11.006. PMID: 33259954 (SRA)

19. Gradient of developmental and injury-response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity

Richards LM*, Whitley OKN*, MacLeod G, Cavalli FMG, Coutinho FJ, Jaramillo JE, Svergun N, Riverin M, Croucher DC, Kushida M, Yu K, Guilhamon P, Rastegar N, Ahmadi M, Bhatti JK, Bozek DA, Li N, Lee L, Che C, Luis E, Park NI, Xu Z, Ketela T, Moore RA, Marra MA, Spears J, Cusimano MD, Das S, Bernstein M, Haibe-Kains B, Lupien M, Luchman HA, Weiss S, Angers S, Dirks PB+, Bader GD+, Pugh TJ+.

Nature Cancer. 2021 Feb. (SRA)

20. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM.

Lancet. 2021 Jan 23;397(10271):281-292. doi: 10.1016/S0140-6736(20)32554-X. PMID: 33485453. (CA)

21. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy.

Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AML, Bruce JP, Wintersinger JA, Singh Mer A, Lo EBL, Leung C, Lima-Fernandes E, Pedley NM, Soares F, McGibbon S, He HH, Pollet A, Pugh TJ, Haibe-Kains B, Morris Q, Ramalho-Santos M, Goyal S, Moffat J, O’Brien CA.

Cell. 2021 Jan 7;184(1):226-242.e21. doi: 10.1016/j.cell.2020.11.018. PMID: 33417860. (CA)

1. Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway

Restall IJ, Cseh O, Richards LM, Pugh TJ, Luchman HA, Weiss S

Cancer Res. 2020 Dec 15;80(24):5478-5490. doi: 10.1158/0008-5472.CAN-19-3923. (CA)

2. Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing

Abelson S, Zeng AGX, Nofech-Mozes I, Wang TT, Ng SWK, Minden MD, Pugh TJ, Awadalla P, Shlush LI, Murphy T, Chan SM, Dick JE, Bratman SV.

Sci Adv. 2020 Dec 9;6(50):eabe3722. doi: 10.1126/sciadv.abe3722. (CA)

3. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.

Kim SR, Tone A, Kim R, Cesari M, Clarke B, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.

Int J Gynecol Cancer. 2020 Dec;30(12):1951-1958. doi: 10.1136/ijgc-2020-001927. PMID: 33082239

4. Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer

Kim SR, Tone A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollet A, Ferguson SE.

Cancer. 2020 Aug 18. PMID: 32809219 (CA)

5. Assessment of Genetic Drift in Large Pharmacogenomic Studies

Quevedo R, Smirnov P, Tkachuk D, Ho C, El-Hachem N, Safikhani Z, Pugh TJ+, Haibe-Kains B+

Cell Systems. 2020 Sep 4;S2405-4712(20)30323-9. PMID: 32937114 (SRA)

6. Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas

Fukuoka K, Mamatjan Y, Tatevossian R, Zapotocky M, Ryall S, Stucklin AG, Bennett J, Nobre LF, Arnoldo A, Luu B, Wen J, Zhu K, Leon A, Torti D, Pugh TJ, Hazrati L, Laperriere N, Drake J, Rutka J, Dirks P, Kulkarni A, Taylor M, Bartels U, Huang A, Zadeh G, Aldape K, Ramaswamy V, Bouffet E, Snuderl M, Ellison D, Hawkins C, Tabori U.

Neuro Oncol. 2020 Oct 14;22(10):1474-1483. doi: 10.1093/neuonc/noaa077. PMID: 32242226 (CA)

7. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LP, Ley J, Oppelt P, Dunn G, Barnell E, Spies N, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR.

Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. PMID: 32665297 (CA)

8. Wnt activation as a therapeutic strategy in medulloblastoma

Manoranjan B, Venugopal C, Bakhshinyan D, Adile AA, Richards L, Kameda-Smith MM, Whitley O, Dvorkin-Gheva A, Subapanditha M, Savage N, Tatari N, McKenna D, Bassey-Archibong B, Winegarden N, Hallett R, Provias JP, Yarascavitch B, Ajani O, Fleming A, Bader GD, Pugh TJ, Doble BW, Singh SK.

Nat Commun. 2020 Aug 28;11(1):4323. doi: 10.1038/s41467-020-17953-4. PMID: 32859895 (CA)

9. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M., Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM.

Clinical Cancer Research. 2020 Aug 15;26(16):4206-4215. PMID: 32444417 (CA)

10. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

Bratman SV*, Yang SYC*, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Aleshin A, Torti D, Marsh K, Eagles J, Cirlan I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL+, Pugh TJ+

Nature Cancer. 2020 Aug 3 1:873–881 (SRA)

11. Phase I/II Trial of the Combination of ¹⁷⁷Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

Crumbaker M, Pathmanandavel S, Yam AO, Nguyen A, Ho B, Chan L, Ende JA, Rofe C, Kongrak K, Kwan EM, Azad AA, Sharma S, Pugh TJ, Danesh A, Keane J, Eu P, Joshua AM, Emmett L.

Eur Urol Oncol. 2020 Aug 2;S2588-9311(20)30093-6. PMID: 32758400 (CA)

12. CReSCENT: CanceR Single Cell ExpressioN Toolkit.

Mohanraj S*, Díaz-Mejía JJ*, Pham MD, Elrick H, Husić M, Rashid S, Luo P, Bal P, Lu K, Patel S, Mahalanabis A, Naidas A, Christensen E, Croucher D, Richards LM, Shooshtari P, Brudno M+, Ramani AK+, Pugh TJ+.

Nucleic Acids Res. 2020 Jul 2; 48(W1):W372-W379. doi: 10.1093/nar/gkaa437. PMID: 32479601 (CA)

13. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor

Quevedo R*, Spreafico A*, Bruce J, Danesh A, El Ghamrasni S, Giesler A, Hanna Y, Have C, Li T, Yang SYC, Zhang T, Asa SL, Haibe-Kains B, Krzyzanowska M, Smith AC, Singh S, Siu LL+, Pugh TJ+.

Genome Medicine. 2020 April 28;12(18):1-15. PMID: 32345369 (SRA)

14. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma

Murata K, Nakatsugawa M, Rahman MA, Nguyen LT, Millar DG, Mulder DT, Sugata K, Saijo H, Matsunaga Y, Kagoya Y, Guo T, Anczurowski M, Wang CH, Burt BD, Ly D, Saso K, Easson A, Goldstein DP, Reedijk M, Ghazarian DA, Pugh TJ, Butler MO, Mak TW, Ohashi PS, Hirano N. I. 2020 Apr 25;9: e53244 doi: 10.7554/eLife.53244. PMID: 32314731 (CA)

15. Translational genomics of nasopharyngeal cancer.

Tsang CM, Lui VWY, Bruce JP, Pugh TJ, Lo KW.

Semin Cancer Biol. 2019 Sep 12. pii: S1044-579X(19)30284-6. Review. PMID: 31521748 (CA)

16. Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling

Loganathan SK, Schleicher K, Malik A, Quevedo R, Langille E, Teng K, Oh RH, Rathod B, Tsai R, Samavarchi-Tehrani P, Pugh TJ, Gingras AC, Schramek D

Science. 2020 Mar 13;367(6483): 1264 – 1269. PMID: 32165588 (CA)

17. IL6 induces an IL22+ CD8+ T cell subset with potent antitumor function.

St Paul M, Saibil SD, Lien SL, Han S, Sayad A, Mulder D, Garcia-Batres CR, Elford AR, Israni-Winger K, Robert-Tissot C, Zon M, Katz SR, Shaw P, Clarke BA, Bernardini MQ, Nguyen LT, Haibe-Kains B, Pugh TJ, Ohashi PS.

Cancer Immunol Res. 2020 Jan 21. pii: canimm.0521.2019. PMID: 31964625 (CA)